Published in Medical Letter on the CDC and FDA, December 4th, 2005
Zactima is designed to be a multitargeted compound, directed to the inhibition of key cell signaling pathways involved in tumor growth and spread. Tumor cells are targeted through inhibition of epidermal growth factor receptor and RET tyrosine kinases, while tumor blood supply is targeted through inhibition of vascular endothelial growth factor receptor tyrosine kinase. RET tyrosine kinase activity is an important...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.